Study of Amblyomin-X in Advanced Solid Tumor

Inclusion Criteria: * Eligible patients must sign the Free and Informed Consent Term (TCLE), * be between 18 and 75 years of age, * present a solid tumor proven by anatomopathological examination at an advanced or metastatic stage and refractory to conventional treatment or without current indication or access to conventional treatment , * have a life expectancy of at least 12 weeks. * presence of measurable disease according to Response Response Criteria in Solid Tumors (RECIST, version 1.1), * medullary, renal and hepatic functions within acceptable limits (defined in protocol), * end of the previous antineoplastic treatment at least 4 weeks (since the last dose of any antineoplastic medication, radiotherapy, or surgical procedure). Exclusion Criteria: * The presence of previously non-irradiated brain metastasis; * Prediction of the use of radiotherapy, surgery, systemic antineoplastic treatment, or any other form of treatment for cancer after inclusion in the study; * Prediction of corticosteroid use, hematopoietic growth factors or inhibitors of bone resorption during the first course of treatment (4 weeks); * Regular use of anticoagulants or known previous coagulation disorder; * Severe comorbidity (at the discretion of the researcher); * Gestational, lactating, pregnant women, or who have not been surgically infertile or menopausal for at least 12 months; * Men and women who refuse to use an adequate contraceptive method during the study period; * Participation of another clinical study in the last 12 months (unless justified by the investigator); * Or inability to comply with study requirements and procedures.